ESMO 2023 | GALAXY: ctDNA as a prognostic biomarker in resected colorectal cancer

Yoshiaki Nakamura, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan, summarizes the results of the GALAXY trial (UMIN000039205) using circulating tumor DNA (ctDNA) to stratify molecular residual disease status in post-operative colorectal cancer. Lower disease-free survival (DFS) in molecular residual disease (MRD)-positive patients identified through ctDNA analysis correlated with their previous findings and these patients were shown to significantly benefit from postoperative adjuvant chemotherapy (ACT) whereas their MRD-negative counterparts were not. Analysis strongly suggests ctDNA is a prognostic, possibly predictive biomarker. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.